![Blood Podcast artwork](https://is1-ssl.mzstatic.com/image/thumb/Podcasts113/v4/02/82/f4/0282f4cd-40ab-c4eb-7ebd-ab26ffec617e/mza_15952236382953722746.jpg/100x100bb.jpg)
Belumosudil for chronic GVHD, mechanistic insights into VITT, and factors driving molecular response in IFNα-treated MPNs
Blood Podcast
English - December 02, 2021 17:30 - 20 minutes - 18.7 MB - ★★★★ - 44 ratingsLife Sciences Science hematology oncology medical medical research Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Post-vaccination COVID-19 in patients with hematologic malignancies
First on today’s podcast, we’ll review results of a randomized phase 2 study demonstrating that inhibition of ROCK2 with belumosudil is well tolerated and effective in patients with steroid-refractory graft-versus-host disease. Next, we’ll review the work of researchers who have uncovered new insights into the immunopathogenesis of vaccine-induced immune thrombotic thrombocytopenia. And we’ll close with a report of a prospective longitudinal analysis that elucidates the dynamics of mutated hematopoietic stem and progenitor cells during therapy with interferon-alpha in patients with BCR-ABL1 negative myeloproliferative neoplasms.